Kits Eyecare (KITS) – Investment Analysts’ Weekly Ratings Updates

Kits Eyecare (TSE: KITS) recently received a number of ratings updates from brokerages and research firms:

• 5/7/2026 – Kits Eyecare had its price target lowered by Canaccord Genuity Group Inc. from C$23.00 to C$22.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Kits Eyecare had its price target lowered by Stifel Nicolaus from C$24.00 to C$21.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Kits Eyecare had its price target lowered by Desjardins from C$25.00 to C$23.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Kits Eyecare had its price target lowered by ATB Cormark Capital Markets from C$20.00 to C$16.75. They now have a “speculative buy” rating on the stock.

Insider Transactions at Kits Eyecare

In related news, Director Roger Hardy bought 25,000 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were purchased at an average cost of C$11.37 per share, for a total transaction of C$284,250.00. Following the acquisition, the director owned 4,093,727 shares of the company’s stock, valued at approximately C$46,545,675.99. This represents a 0.61% increase in their position. Over the last three months, insiders purchased 36,000 shares of company stock worth $411,910.

KITS (TSX: KITS) is one of the world’s fastest growing eyecare providers, offering high-quality, affordable prescription glasses and contact lenses through its vertically integrated digital platform. With advanced in-house lens manufacturing, an industry-leading digital fit experience powered by OpticianAI, and thousands of 5-star customer reviews, KITS is redefining how Canadians experience eyecare. Designed in Canada. Delivered worldwide.